VIA
GILD icon

Vantis Investment Advisers’s Gilead Sciences GILD Stock Holding History

Vantis Investment Advisers’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-95,600
Closed -$7.15M – 17
2020
Q1 		$7.15M Buy
+95,600
New +$6.61M 30.11% 1

Other funds holding GILD

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Vantis Investment Advisers's GILD Position: Q2 2020 in Review

Vantis Investment Advisers sold out of Gilead Sciences (GILD) in Q2 2020, closing a stake of 95,600 shares — an estimated $7.15M sold.

Vantis Investment Advisers first reported a position in GILD in Q1 2020 and held it in 1 quarter. The position peaked at $7.15M in Q1 2020. 1,626 funds tracked by Wall St. Rank hold GILD as of Q2 2020.

  • Vantis Investment Advisers reported no remaining Gilead Sciences position as of Q2 2020 after selling out during the quarter.
  • Vantis Investment Advisers sold 95,600 Gilead Sciences shares in Q2 2020, an estimated $7.15M.
  • Vantis Investment Advisers first reported a position in Gilead Sciences in Q1 2020 and held it in 1 quarter.
  • Vantis Investment Advisers's Gilead Sciences position peaked at $7.15M in Q1 2020.
  • 1,626 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2020.

Based on Vantis Investment Advisers's 13F filing for Q2 2020, filed 13 Aug 2020.